Multiple Myeloma (MM) Recruiting Phase 2 Trials for DB04572 (Thiotepa)

Also known as: MULTIPLE MYELOMA (MM) / Multiple myeloma / Myeloma, Multiple / Multiple Myelomas / Multiple Myeloma(MM) / Plasma cell myelomas / Myelomatosis multiple / Peripheral plasma cell myeloma / Myelomatosis / Multiple myeloma myelomatosis / Plasma cell myeloma / Myeloma / Multiple myeloma with failed remission

IndicationStatusPhase
DBCOND0040908 (Multiple Myeloma (MM))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01746849Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationTreatment
NCT02861417Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic TransplantationTreatment
NCT01119066HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesTreatment
NCT02507479Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid MalignanciesTreatment